Targeted drug for advanced biliary tract cancer after standard treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have biliary tract cancer (cancer in the bile ducts or gallbladder) that has spread or cannot be removed with surgery.
- Your tumor is positive for a protein called Claudin18.2 (doctors will test for this).
- You've already had at least one type of chemotherapy or drug treatment for your cancer, and it either stopped working or you couldn't handle the side effects.
- You are generally well enough to do daily activities (like walking around or light housework).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BL-B01D1 against standard treatment options for patients with advanced biliary tract cancer (cancer of the bile ducts) that has stopped responding to platinum chemotherapy and immunotherapy. The drug is designed to target and destroy cancer cells more effectively.
This study tests a new drug called SHR-A1904 for patients with advanced neuroendocrine cancer (a rare type of cancer) who have already tried at least one round of chemotherapy. The goal is to see if this drug can slow or shrink the cancer.
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
This trial is testing whether a new drug (SHR-8068) combined with adebrelimab and chemotherapy works better than the current standard treatment for people with advanced bile duct cancer who have not been treated yet.
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.